SecBot SecBot
6-K ·Filed Jul 20, 2026

KMDA

KAMADA LTD
BULLISH
Impact 6/10
Horizonmonths Processed3mo ago SEC0001213900-26-079393
Notable filing: 6-K
Actionable Insight ▲ Bullish

This agreement provides a clear, multi-year revenue stream from plasma sales, validating Kamada's vertical-integration strategy and supporting its FY2026 guidance. Traders should monitor Q4 2026 earnings for initial commercial sales under this agreement and any updates on the ramp-up of the plasma collection centers to full capacity.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$7.09
T+0 close · Jul 20, 2026 · via day close
Latest settled
+8.46%
T+60 · $7.69
Vs SPY
+3.62%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 20 $7.09entry
  2. T+1 · 4mo ago +2.68%α +1.85% · $7.28
  3. T+5 · 4mo ago −0.42%α +0.00% · $7.06
  4. T+20 · 3mo ago +9.45%α +5.33% · $7.76
  5. T+60 · 5w ago +8.46%α +3.62% · $7.69
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kamada announced a three-year agreement to supply normal source plasma from its Texas collection centers to a leading biopharmaceutical company, expected to generate approximately $50 million in revenue over three years. Initial commercial sales are expected in Q4 2026, and this agreement validates the company's investment in its U.S. plasma collection operations, supporting its vertical-integration strategy and multi-year revenue growth objectives. The agreement is included in the company's current annual guidance, which projects total revenues of $200-$205 million and adjusted EBITDA of $50-$53 million for fiscal year 2026.

Key Facts

  • Kamada entered a three-year agreement to supply normal source plasma to a leading biopharmaceutical company.
  • The agreement is expected to generate approximately $50 million in revenue over three years.
  • Initial commercial sales are expected to be recorded in Q4 2026.
  • Plasma will be sourced from Kamada's FDA-approved collection centers in Houston and San Antonio, Texas.
  • Each center supports a planned capacity of approximately 50,000 liters per year at full capacity.
  • The agreement is included in Kamada's current annual guidance of $200-$205 million in total revenues and $50-$53 million in adjusted EBITDA for fiscal year 2026.
  • Kamada had anticipated the commencement of plasma sales by year-end 2026 when issuing its full-year revenue forecast.

Financial Impact

Approximately $50 million in revenue over three years from the supply agreement, included in the company's current annual guidance of $200-$205 million total revenue and $50-$53 million adjusted EBITDA for FY2026.

revenueadjusted EBITDA

Risk Factors

  • Operational ramp-up and efficiency of the plasma collection centers may not meet planned capacity of 50,000 liters per year per center.
  • The agreement is with an undisclosed counterparty, introducing counterparty risk.
  • Geopolitical risks from conflicts in the Middle East and potential tariffs could impact operations and profitability.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-079393
Document: ea029849801ex99-1.htm0001213900-26-079393
Document: 0001213900-26-079393-index-headers.html0001213900-26-079393
Document: 0001213900-26-079393-index.html0001213900-26-079393
Document: 0001213900-26-079393.txt0001213900-26-079393

Track record

25 reports on KMDA

Performance horizon

8 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +16.13% at T+20 after the Aug 12, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 9, 20267d ago 6-K Bullish 6/10 No price data
  2. Nov 9, 20267d ago Press Release Bullish 6/10 Entry $7.71 to $8.11 Now $8.11 +5.19% ▲ +5.19% +6.88% vs SPY
  3. Nov 2, 202614d ago 6-K Neutral 2/10 Entry $7.36 to $7.71 Now $8.11 +10.19% ▲ +4.76% +4.68% vs SPY
  4. Oct 6, 20265w ago 6-K Neutral 4/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  5. Oct 6, 20265w ago Press Release Bullish 6/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  6. Oct 5, 20266w ago 6-K Neutral 2/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  7. Sep 17, 20268w ago 6-K Bullish 6/10 Entry $8.67 to $8.83 Now $8.11 −6.46% ▲ +1.85% +1.24% vs SPY
  8. Sep 16, 20268w ago EFFECT Neutral 3/10 Entry $8.19 to $8.77 Now $8.11 −0.98% ▲ +7.08% +4.52% vs SPY
  9. Sep 10, 20269w ago 6-K Neutral 2/10 Entry $7.99 to $8.67 Now $8.11 +1.50% ▲ +8.51% +9.01% vs SPY
  10. Sep 3, 202610w ago Press Release Neutral 2/10 Entry $8.54 to $8.31 Now $8.11 −5.04% ▼ −2.69% −1.48% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 9h 25m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 20, 2026